Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO™ (patisiran)
Alnylam Pharmaceuticals announced the FDA approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference therapeutic, for treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. August 10, 2018